Biocompatible nanopolymers: the next generation of breast cancer treatment?

Nanomedicine

Volumn 7, Issue 10, 2012, Pages 1467-1470

  Ljubimova, Julia Y ^a   Holler, Eggehard ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

biomarkers; breast cancer; nanodrugs; nanopolymers; personalized medicine; polymalic acid

Indexed keywords

2C5 ANTIBODY; ACETALDEHYDE; ANTIBODY; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIOPOLYMER; CISPLATIN; DENDRIMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FUNCTIONAL GROUP; GELDANAMYCIN; MALIC ACID; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NANOPARTICLE; NANOPOLYMER; NANOSPHERE; OLIGONUCLEOTIDE; PACLITAXEL; PLATINUM DERIVATIVE; POLYAMIDE; POLYESTER; POLYETHER; POLYGLACTIN; POLYGLUTAMIC ACID; POLYMALIC ACID; POLYSACCHARIDE; PRODRUG; TEMOZOLOMIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; BREAST CANCER; CANCER THERAPY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; ENDOSOME; GEL; GENE EXPRESSION PROFILING; HUMAN; LYSOSOME; MEMBRANE PERMEABILITY; MICELLE; NONHUMAN; PERMEABILITY BARRIER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS;

BIOCOMPATIBLE MATERIALS; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, ERBB-2; HUMANS; INDIVIDUALIZED MEDICINE; NANOPARTICLES;

EID: 84869380137     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.115     Document Type: Review

References (20)

1. Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv. Drug Deliv. Rev. 62, 203-230 (2010).
2. Kopecek J, Kopecková P. HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev. 62, 122-149 (2010).
3. Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J. Drug Deliv. doi:10.1155/2012/915375 (2012) (Epub ahead of print).
4. Varshosaz J. Dextran conjugates in drug delivery. Expert Opin. Drug Deliv. 9, 509-523 (2012).
5. Patel MP, Patel RR, Patel JK. Chitosan mediated targeted drug delivery system: A review. J. Pharm. Pharm. Sci. 13, 536-557 (2010).
6. Rudzinski WE, Aminabhavi TM. Chitosan as a carrier for targeted delivery of small interfering RNA. Int. J. Pharm. 399, 1-11 (2010).
7. Wang JJ, Zeng ZW, Xiao RZ et al. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomedicine 6, 765-774 (2011).
8. Li C, Wallace S. Polymer-drug conjugates: Recent development in clinical oncology. Adv. Drug Deliv. Rev. 60, 886-898 (2008).
9. Yea H, Jina L, Hua R et al. Poly(g,l-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 27, 5958-5965 (2006).
10. Poo H, Park C, Kwak M-S et al. New biological functions and applications of high-molecular-mass poly-g-glutamic acid. Chem. Biodivers. 7, 1555-1562 (2010).
11. Ding H, Inoue S, Ljubimov AV et al. Inhibition of brain tumor growth by intravenous poly(b-l-malic) acid nanobioconjugate with pH-dependent drug release. Proc. Natl Acad. Sci. USA 107, 18143-18148 (2010).
12. Inoue S, Ding H, Portilla-Arias J et al. Nanobioconjugate inhibition of HER2/neu signaling and synthesis provides efficient mouse breast cancer treatment. Cancer Res. 71, 1454-1464 (2011).
13. Inoue S, Patil R, Portilla-Arias J et al. Novel nanobioconjugate inhibiting EGFR expression in triple negative breast cancer. PLoS ONE 7(2), E3107 (2012).
14. Patil R, Portilla-Arias J, Ding H et al. Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(b-l-malic acid). Pharm. Res. 27, 2317-2329 (2010).
15. Yap TA, Workman P. Exploiting the cancer genome: Strategies for the discovery and clinical development of targeted molecular therapeutics. Annu. Rev. Pharmacol. Toxicol. 52, 549-573 (2012).
16. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
17. Herschkowitz JI, Zhao W, Zhang M et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor initiating cells. Proc. Natl Acad. Sci. USA 109, 2778-2783 (2012).
18. Stopeck AT, Brown-Glaberman U, Wong HY et al. The role of targeted therapy and biomarkers in breast cancer treatment. Clin. Exp. Metastasis doi:10.1007/s10585-012-9496-y (2012) (Epub ahead of print).
19. Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol. Med. 18, 385-393 (2012).
20. Ding H, Portilla-Aries J, Patil R, Black KL, Ljubimova JY, Holler E. Polymalic acid peptide copolymers: design and optimization for endosomolytic drug delivery. Biomaterials 32, 5269-5278 (2011).